Hematopoiesis Capacity, Immunomodulatory Effect and Ex Vivo Expansion Potential of Mesenchymal Stem Cells Are Not Impaired by Cryopreservation

REFERENCES

• Jiang Y., Jahagirdar B. N., Reinhardt R. L., Schwartz R. E., Keene C. D., Ortiz-Gonzalez X. R., et al. Pluripotency of mesenchymal stem cell derived from adult marrow. Nature 2002; 418: 41–49
   PubMed Web of Science ®Google Scholar
• Pittenger M. F., Mackay A. M., Beck S. C., Jaiswal R. K., Douglas R., Mosca J. D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143–147
   PubMed Web of Science ®Google Scholar
• Meirelles L. S., Nardi N. B. Murine marrow-derived mesenchymal stem cell: I solation, in vitro expansion, and characterization. Br J Haematol 2003; 123: 702–711
   PubMed Web of Science ®Google Scholar
• Majumdar M. K., Thiede M. A., Hayneseorth S. E., Haynesworth S. E., Bruder S. P., Gerson S. L. Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. J Hemtoth Stem Cell 2000; 9: 841–848
   PubMedGoogle Scholar
• Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42–48
   PubMed Web of Science ®Google Scholar
• Krampera M., Glennie S., Dyson J., et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101: 3722–3729
   PubMed Web of Science ®Google Scholar
• Wang J., Liu K., Lu D. P. Mesenchymal stem cells in stem cell transplant recipients are damaged and remain of host origin. Int J Hematol 2005; 82: 152–158
   PubMed Web of Science ®Google Scholar
• Cilloni D., Carlo-Stella C., Falzetti C., et al. Limited engraftment capacity of bone marrow–derived mesenchymal cells following T-cell–depleted hematopoietic stem cell transplantation. Blood 2000; 96: 3637–3643
   PubMed Web of Science ®Google Scholar
• O'Flaherty E., Sparrow R., Szer J. Bone marrow stromal function from patients after bone marrow transplantation. Bone Marrow Transplant 1995; 15: 207–212
   PubMed Web of Science ®Google Scholar
• Bruder S. P., Jaiswal N., Haynesworth S. E. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J Cell Biochem 1998; 64: 278–294
   Web of Science ®Google Scholar
• Kotobuki N., Hirose M., Machida H., et al. Viability and osteogenic potential of cryopreserved human bone marrow-derived mesenchymal cells. Tissue Eng 2005; 11: 663–673
   PubMedGoogle Scholar
• Xiang Y., Zheng Q., Jia B., et al. BingEx vivo expansion, adipogenesis and neurogenesis of cryopreserved human bone marrow mesenchymal stem cells. Cell Biol Intern 2007; 31: 444–450
   PubMed Web of Science ®Google Scholar
• Zhao Z. G., Tang X. Q., You Y., Li W. M., Liu F., Zou P. Assessment of bone marrow mesenchymal stem cell biological characteristics and support hemotopoiesis function in patients with chronic myeloid leukemia. Leukemia Resear 2006; 30: 993–1003
   PubMed Web of Science ®Google Scholar
• Broxmeyer H. E., Srour E. F., Hangoc G., Cooper S., Anderson S. A., Bodine D. M. High-efficiency recovery of functional hematopoietic progenitor and stem cells from human cord blood cryopreserved for 15 years. Proc Natl Acad Sci USA 2003; 100: 645–650
   PubMed Web of Science ®Google Scholar
• Reyes M., Lund T., Lenvik T., Aguiar D., Koodie L., Verfaillie C. M. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 2001; 98: 2615–2625
   PubMed Web of Science ®Google Scholar
• Eaves C. J., Cashman J. D., Dougherty G. J., Otsuka T., Gaboury L. A., Hogge D. E., et al. Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long term human bone marrow cultures. II. Analysis of positive and negative regulators produced by stromal cells within the adherent layer. Blood 1991; 78: 110–117
   PubMed Web of Science ®Google Scholar
• Gupta P., Blazar B. R., Gupta K., Verfaillie C. M. Human, CD34 bone marrow cells regulate stromal production of interleukin-6 and granulocyte colony-stimulating factor and increase the colony-stimulating activity of stroma. Blood 1998; 91: 3724–373
   PubMed Web of Science ®Google Scholar
• Rowley J. D. A new consistent chromosome abnormality in chronic myelogenous leukemia. Nature 1973; 243: 290–293
   PubMed Web of Science ®Google Scholar
• de Klein A., van Kessel A. G., Grosveld G., Bartram C. R., Hagemeijer A., Bootsma D. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature 1982; 23: 765–767
   Web of Science ®Google Scholar
• Toksoz D., Zsebo K. M., Smith K. A., Hu S., Brankow D., Suggs S. V., Martin F. H., Williams D. A. Support of human hematopoiesis in long term bone marrow cultures by murine stromal cells selectively expressing the membrane bound and secreted forms of the human homologue of the steel gene product stem cell factor. Proc Natl Acad Sci USA 1992; 89: 7350–7354
   PubMed Web of Science ®Google Scholar
• Koc O., Lazarus H. Mesenchymal stem cells heading to the clinic. Bone Marrow Transplant 2001; 27: 235–239
   PubMed Web of Science ®Google Scholar
• Noort W. A., Kruisselbrink A. B., in't Anker P. S., Kruger M., van Bezooijen R. L., de Paus R. A., Heemskerk M. H., Lowik C. W., Falkenburg J. H., Willemze R, Fibbe W. E. Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34 (+) cells in NOD/SCID mice. Exp Hematol 2002; 30: 870–878
   PubMed Web of Science ®Google Scholar
• Koc O. N., Gerson S. L., Cooper B. W., Dyhouse S. M., Haynesworth S. E., Caplan A. I., Fox R. M., Szekely E. M., Tainer N., Lazarus H. M. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000; 18: 307–316
   PubMed Web of Science ®Google Scholar
• Koc O. N., Day J., Nieder M., Gerson S. L., Lazarus H. M., Krivit W. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic eukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplantation 2002; 30: 215–222
   PubMed Web of Science ®Google Scholar
• Otsuka T., Eaves C. J., Humphries R. K., Hogge D. E., Eaves A. C. Lack of evidence for abnormal autocrine or paracrine mechanisms underlying the uncontrolled proliferation of primitive chronic myeloid leukemia progenitor cells. Leukemia 1991; 5: 861–868
   PubMed Web of Science ®Google Scholar
• Wetzler M., Kurzrock R., Taylor K., Spitzer G., Kantarjian H., Baiocchi G., et al. Constitutive and induced expression of growth factors in cultures of normal and chronic phase CML Ph bone marrow stroma. Cancer Res 1990; 50: 5801–5805
   PubMed Web of Science ®Google Scholar
• Bhatia R., McGlave P. B., Dewald G. W., Blazar B. R., Verfaillie C. M. Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. Blood 1995; 85: 3636–45
   PubMed Web of Science ®Google Scholar
• Le Blanc K., Tammik L., Sundberg B., Haynesworth S. E., Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003; 57: 11–20
   PubMed Web of Science ®Google Scholar
• Potian J. A., Aviv H., Ponzio N. M., Harrison J. S., Rameshwar P. Veto-like activity of mesenchymal stem cells, functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol 2003; 171: 3426–3434
   PubMed Web of Science ®Google Scholar
• Tse W. T., Pendleton J. D., Beyer W. M., Egalka M. C., Guinan E. C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003; 75: 389–397
   PubMed Web of Science ®Google Scholar
• Deans R. J., Moseley A. B. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol 2000; 28: 875–884
   PubMed Web of Science ®Google Scholar
• Le Blanc K., Tammik C., Rosendahl K., Zetterberg E., Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003; 31: 890–896
   PubMed Web of Science ®Google Scholar
• Le Blanc K., Rasmusson I., Sundberg B., Gotherstrom C., Hassan M., Uzunel M., Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439–1441
   PubMed Web of Science ®Google Scholar
• Frassoni F., Labopin M., Bacigalupo A. Expanded mesenchymal stem cells (MSC), co-infused with HLA identical hematopoietic stem cell transplants, reduce acute and chronic graftversus-host disease: a matched pair analysis. Bone Marrow Transplant 2002; 29(Suppl 2)S2
   Google Scholar